Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network across Rural Greece: The Grecoself study
Ημερομηνία
2019Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25-29 years to 5.1% for women aged 50-60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25-29) to 76.3% (for women 40-49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention. ©2019 American Association for Cancer Research.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology
Agorastos, T.; Chatzistamatiou, K.; Katsamagkas, T.; Koliopoulos, G.; Daponte, A.; Constantinidis, T.; Constantinidis, T. C. (2015)Objectives The objective of the present study is to assess the performance of a high-risk human papillomavirus (HR-HPV) DNA test with individual HPV-16/HPV-18 genotyping as a method for primary cervical cancer screening ... -
Acceptability of Self-Sampling for Human Papillomavirus-Based Cervical Cancer Screening
Chatzistamatiou K., Vrekoussis T., Tsertanidou A., Moysiadis T., Mouchtaropoulou E., Pasentsis K., Kitsou A., Moschaki V., Ntoula M., Zempili P., Halatsi D., Truva T., Piha V., Agelena G., Daponte A., Vanakara P., Paschopoulos M., Stefos T., Lymberis V., Kontomanolis E.N., Makrigiannakis A., Deligeoroglou E., Panoskaltsis T., Adonakis G., Michail G., Stamatopoulos K., Agorastos T. (2020)Background: Human papillomavirus (HPV)-DNA testing combined with self-sampling could increase cervical cancer screening effectiveness, utilizing a sensitive screening modality and an easy sampling method with minimal pain ... -
Association of p16 (CDKN2A) polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population
Tsakogiannis D., Moschonas G.D., Bella E., Kyriakopoulou Z., Amoutzias G.D., Dimitriou T.G., Kottaridi C., Markoulatos P. (2018)The tumor suppressor protein p16 plays a fundamental role in cell cycle regulation and exerts a protective effect against tumor growth. Two different polymorphisms at positions 540 and 580 at the 3′UTR of exon 3 of p16 ...